2025
Efficacy of beta-blocker agents on clinical outcomes in patients with thoracic aortic aneurysm: A systematic review and meta-analysis of randomized controlled trials
Tanriverdi L, Barrett A, Kalyanasundaram A, Zafar M, Ziganshin B, Elefteriades J. Efficacy of beta-blocker agents on clinical outcomes in patients with thoracic aortic aneurysm: A systematic review and meta-analysis of randomized controlled trials. Vascular Pharmacology 2025, 159: 107494. PMID: 40204023, DOI: 10.1016/j.vph.2025.107494.Peer-Reviewed Original ResearchConceptsThoracic aortic aneurysmRandomized Controlled TrialsPooled risk ratioB-blockersAortic dissectionClinical outcomesAortic aneurysmRisk ratioRisk of aortic dissectionMeta-analysis of randomized controlled trialsControlled TrialsB-blocker treatmentCompared to placeboBeta-blocking agentsCochrane Risk of Bias 2 toolRisk of Bias 2 toolRobust randomized controlled trialsInverse variance-weighted random-effects modelRisk of bias assessmentRandom-effects modelEvidence of benefitSystematic literature searchAortic eventsEvidence-based recommendationsFollow-up
2024
Nonselective β-Adrenergic Receptor Inhibitors Impair Hematopoietic Regeneration in Mice and Humans after Hematopoietic Cell Transplants
Nishino J, Hu W, Kishtagari A, Shen B, Gao X, Blackman C, Kassim A, Marneni N, Cherukuri A, Vittrup R, Kalkan F, Shah R, Ahn C, Gao A, Ahmedrabie A, Collins R, Zeidan A, Bidikian A, Gowda L, Shaffer B, Madanat Y, Zhao Z, Chung S, Morrison S. Nonselective β-Adrenergic Receptor Inhibitors Impair Hematopoietic Regeneration in Mice and Humans after Hematopoietic Cell Transplants. Cancer Discovery 2024, 15: 748-766. PMID: 39786370, PMCID: PMC11962394, DOI: 10.1158/2159-8290.cd-24-0719.Peer-Reviewed Original ResearchAllogeneic hematopoietic cell transplantationHematopoietic cell transplantationB-blockersCell transplantationHematopoietic regenerationGraft-versus-host disease prophylaxisAutologous hematopoietic cell transplantationDelayed platelet engraftmentImpaired hematopoietic regenerationPost-transplant chemotherapyGraft-versus-hostAdrenergic receptor signalingBone marrow regenerationInhibitory effectPlatelet engraftmentInhibit engraftmentReceptor inhibitorsDisease prophylaxisMarrow regenerationMouse hematopoiesisHematopoietic cellsEngraftmentLarger dosesReceptor signalingPeripheral nervesEfficacy of beta blockers in patients with thoracic aortic aneurysm: meta-analysis of randomized controlled trials
Tanriverdi L, Barrett A, Kalyanasundaram A, Zafar M, Ziganshin B, Elefteriades J. Efficacy of beta blockers in patients with thoracic aortic aneurysm: meta-analysis of randomized controlled trials. European Heart Journal 2024, 45: ehae666.2256. DOI: 10.1093/eurheartj/ehae666.2256.Peer-Reviewed Original ResearchThoracic aortic aneurysmRandomized Controlled TrialsPooled risk ratioB-blockersAortic aneurysmAortic dissectionControlled TrialsAortic eventsRisk ratioPrimary outcomePooled risk estimatesRisk of aortic dissectionRisk of bias assessmentNo treatmentMeta-analysis of randomized controlled trialsInverse variance-weighted random-effects modelMeta-analysisLiterature searchB-blocker treatmentSystematic review protocolInternational Prospective RegisterCochrane Central Register of Controlled TrialsEfficacy of beta blockersCentral Register of Controlled TrialsSummary effect measuresLong‐Term Safety and Efficacy of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results of the PIONEER‐OLE Study
Masri A, Lester S, Stendahl J, Hegde S, Sehnert A, Balaratnam G, Shah A, Fox S, Wang A. Long‐Term Safety and Efficacy of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results of the PIONEER‐OLE Study. Journal Of The American Heart Association 2024, 13: e030607. PMID: 38591260, PMCID: PMC11262496, DOI: 10.1161/jaha.123.030607.Peer-Reviewed Original ResearchConceptsObstructive hypertrophic cardiomyopathyKansas City Cardiomyopathy Questionnaire–Overall Summary scoreSymptomatic obstructive hypertrophic cardiomyopathyOutflow tract gradientHypertrophic cardiomyopathyNew York Heart Association class improvementLeft ventricular outflow tract gradientTreatment-emergent adverse eventsSerum NT-proBNP levelsLeft ventricular ejection fractionEffect of mavacamtenIndividual dose titrationNT-proBNP levelsVentricular ejection fractionSerum NT-proBNPSummary scoreLong-term safetyLonger-term treatmentDose titrationEjection fractionNT-proBNPB-blockersReduced doseAdverse eventsInterim resultsA multi-ancestry genetic study of pain intensity in 598,339 veterans
Toikumo S, Vickers-Smith R, Jinwala Z, Xu H, Saini D, Hartwell E, Pavicic M, Sullivan K, Xu K, Jacobson D, Gelernter J, Rentsch C, Stahl E, Cheatle M, Zhou H, Waxman S, Justice A, Kember R, Kranzler H. A multi-ancestry genetic study of pain intensity in 598,339 veterans. Nature Medicine 2024, 30: 1075-1084. PMID: 38429522, PMCID: PMC12105102, DOI: 10.1038/s41591-024-02839-5.Peer-Reviewed Original ResearchPain intensityChronic painTreat chronic painCalcium channel blockersCross-ancestry meta-analysisGenome-wide association studiesExperience of painSamples of European ancestryPain phenotypesFunctional genomics dataGABAergic neuronsCalcium channelsAnalgesic effectB-blockersDrug groupMillion Veteran ProgramPainSubstance use disordersQuality of lifeDrug repurposing analysisOpioid crisisGenetic architectureCausal genesGenetic lociGenomic data
2019
Optimal Medical Therapy in Heart Failure: Reasons for Lack of Medication Titration in the GUIDE IT Trial
Fiuzat M, Alemayehu W, Ezekowitz J, Westerhout C, Whellan D, Mulder H, Ahmad T, Adams K, Pina I, Anstrom K, Cooper L, Alhanti B, Sbolli M, Mark D, Leifer E, Felker M, O'Connor C, Januzzi J. Optimal Medical Therapy in Heart Failure: Reasons for Lack of Medication Titration in the GUIDE IT Trial. Journal Of Cardiac Failure 2019, 25: s78. DOI: 10.1016/j.cardfail.2019.07.221.Peer-Reviewed Original ResearchHeart failureMedication titrationMedical therapyMedication adjustmentsClinical outcomesTarget dosesGUIDE-IT trialOptimal medical therapyReduced ejection fractionWeeks of enrollmentEnd of studyProtocol-driven approachUse of guidelinesFree-text reasonsGDMT groupGUIDE-ITHF medicationsB-blockersNT-proBNPEjection fractionNatriuretic peptideStudy visitClinicians' decisionsIT trialSerial measurements
2016
Glucagon-induced hypertensive emergency: a case report
Legler A, Kim R, Chawla N. Glucagon-induced hypertensive emergency: a case report. Journal Of Clinical Anesthesia 2016, 35: 493-496. PMID: 27871582, DOI: 10.1016/j.jclinane.2016.08.033.Peer-Reviewed Original ResearchConceptsSphincter of OddiPotential hemodynamic effectsAdequate pain controlEvidence of pheochromocytomaPatient's blood pressureOut-of-operating roomAsymptomatic pheochromocytomaEmpirical treatmentHypertensive emergenciesIntraoperative cholangiographyPain controlB-blockersIntraoperative useCase reportHemodynamic effectsPatient populationRadiographic evidenceBlood pressureCardiovascular crisisPatientsPerioperative physiciansGlucagon administrationHealthy populationTherapeutic useAdverse effects
1999
Under-Utilisation of b-Blockers After Acute Myocardial Infarction
Bradford W, Chen J, Krumholz H. Under-Utilisation of b-Blockers After Acute Myocardial Infarction. PharmacoEconomics 1999, 15: 257-268. PMID: 10537433, DOI: 10.2165/00019053-199915030-00005.Peer-Reviewed Original ResearchConceptsB-blocker therapyB-blockersAcute myocardial infarction survivorsRelative risk reductionAcute myocardial infarctionMyocardial infarction survivorsLess effective treatmentsFirst yearHospital readmissionMyocardial infarctionInfarction survivorsDearth of evidenceEffective treatmentTherapyMedical resourcesRisk reductionHealth statesRecent studiesLittle evidenceAMIUnderprescriptionReinfarctionReadmissionMorbidityInfarction
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply